BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9293790)

  • 1. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.
    Lim SM; DeNardo GL; DeNardo DA; Shen S; Yuan A; O'Donnell RT; DeNardo SJ
    J Nucl Med; 1997 Sep; 38(9):1374-8. PubMed ID: 9293790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of myelotoxicity using semi-quantitative marrow image scores.
    Lim S; DeNardo GL; DeNardo DA; O'Donnell RT; Yuan A; DeNardo SJ
    J Nucl Med; 1997 Nov; 38(11):1749-53. PubMed ID: 9374345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging for improved prediction of myelotoxicity after radioimmunotherapy.
    DeNardo DA; DeNardo GL; O'Donnell RT; Lim SM; Shen S; Yuan A; DeNardo SJ
    Cancer; 1997 Dec; 80(12 Suppl):2558-66. PubMed ID: 9406710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy.
    Wilder RB; DeNardo GL; Sheri S; Fowler JF; Wessels BW; DeNardo SJ
    Eur J Nucl Med; 1996 Aug; 23(8):953-7. PubMed ID: 8753685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
    DeNardo GL; DeNardo SJ; Macey DJ; Shen S; Kroger LA
    Cancer; 1994 Feb; 73(3 Suppl):1038-48. PubMed ID: 8306246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy.
    Macey DJ; DeNardo SJ; DeNardo GL; DeNardo DA; Shen S
    Clin Nucl Med; 1995 Feb; 20(2):117-25. PubMed ID: 7720301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
    DeNardo DA; DeNardo GL; Yuan A; Shen S; DeNardo SJ; Macey DJ; Lamborn KR; Mahe M; Groch MW; Erwin WD
    J Nucl Med; 1996 Dec; 37(12):1970-5. PubMed ID: 8970516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
    Juweid M; Sharkey RM; Siegel JA; Behr T; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5827s-5831s. PubMed ID: 7493354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
    Shen S; Meredith RF; Duan J; Macey DJ; Khazaeli MB; Robert F; LoBuglio AF
    J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
    Behr TM; Béhé M; Sgouros G
    Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
    Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
    Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
    Shen S; DeNardo GL; Yuan A; Hartmann-Siantar C; O'Donnell RT; DeNardo SJ
    Cancer Biother Radiopharm; 2005 Dec; 20(6):662-70. PubMed ID: 16398618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.
    Shen S; Meredith RF; Duan J; Brezovich I; Khazaeli MB; LoBuglio AF
    Cancer Biother Radiopharm; 2003 Apr; 18(2):209-15. PubMed ID: 12804046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
    DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP
    J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma.
    Erwin WD; Spies SM; Kelly ME; Rao P; Eckersberg-Rhodes TE; Nannapaneni M; Groch MW
    Nucl Med Commun; 2001 Feb; 22(2):247-55. PubMed ID: 11258413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    O'Donnell RT; Shen S; Denardo SJ; Wun T; Kukis DL; Goldstein DS; Denardo GL
    Anticancer Res; 2000; 20(5C):3647-55. PubMed ID: 11268433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
    DeNardo SJ; DeNardo GL; Kukis DL; Shen S; Kroger LA; DeNardo DA; Goldstein DS; Mirick GR; Salako Q; Mausner LF; Srivastava SC; Meares CF
    J Nucl Med; 1999 Feb; 40(2):302-10. PubMed ID: 10025839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy.
    Wong JY; Wang J; Liu A; Odom-Maryon T; Shively JE; Raubitschek AA; Williams LE
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):599-607. PubMed ID: 10701739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.